BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38190034)

  • 1. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
    Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
    Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
    Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Eren T; Karacin C; Ucar G; Ergun Y; Yazici O; İmamoglu Gİ; Ozdemir N
    Medicine (Baltimore); 2020 May; 99(22):e20346. PubMed ID: 32481414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.
    Li Z; Li S; Ying X; Zhang L; Shan F; Jia Y; Ji J
    Gastric Cancer; 2020 May; 23(3):540-549. PubMed ID: 32072387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
    Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
    Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
    Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
    Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients.
    Peng Y; Chen R; Qu F; Ye Y; Fu Y; Tang Z; Wang Y; Zong B; Yu H; Luo F; Liu S
    Cancer Biol Ther; 2020; 21(2):189-196. PubMed ID: 31684807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of inflammation markers in postoperative gliomas with or without adjuvant treatments.
    Luo Y; Deng R; Zhong Q; Luo D; Li X; Chen X; Tao S; Feng Z; Jiayi L; Huang Y; Li J; Liu W
    Medicine (Baltimore); 2021 Jun; 100(25):e26437. PubMed ID: 34160435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
    Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
    Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
    [No Abstract]   [Full Text] [Related]  

  • 14. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
    Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
    Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
    Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Dong J; Sun Q; Pan Y; Lu N; Han X; Zhou Q
    BMC Cancer; 2021 Jun; 21(1):700. PubMed ID: 34126950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
    Marín Hernández C; Piñero Madrona A; Gil Vázquez PJ; Galindo Fernández PJ; Ruiz Merino G; Alonso Romero JL; Parrilla Paricio P
    Clin Transl Oncol; 2018 Apr; 20(4):476-483. PubMed ID: 28785911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Zhang X; Gari A; Li M; Chen J; Qu C; Zhang L; Chen J
    J Transl Med; 2022 Feb; 20(1):61. PubMed ID: 35109887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.
    Fu M; Li Z; Ma J; Shen F; Zhang X
    Scand J Gastroenterol; 2024 Jun; 59(6):722-729. PubMed ID: 38362884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma.
    Chen L; Zeng H; Du Z; Zhao Y; Ma X
    Cancer Biomark; 2020; 29(1):151-161. PubMed ID: 32623392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.